Our Health At Risk For Corporate Profit!
To think we live in a country where our wellbeing is in the hands of corporations, is saddening. In the US our health is in jeopardy not because we lack resources or human power to sustain our healthcare demands. We aren’t at risk due to war or some political embargo. It is rather just for profit. Our health is at risk, for corporate profit.
While Turing Pharmaceuticals raised the price of Daraprim—a drug used for the treatment of toxoplasmosis and other symptoms mainly in HIV patients —back in September 2015 to $750 a tablet from $13.50, we find many companies licensing the manufacturing of their drugs overseas, to sell for significantly much less than in US markets. Gilead Sciences Inc. sells Sovaldi —a miracle cure of Hepatitis C with minimal side effects —in the U.S. as at a retail price of $1,000 a pill. That same pill is sold in India for $4 where a patient would undergo an entire course of treatment for the cost of one pill sold here in the US.
With globalism turning the world into one large and heterogeneous community, we seek to tackle more of these issues and their implications on medical tourism and public health.
To learn more about the impact of drug prices on US markets click here: http://www.bloomberg.com/news/articles/2015-12-29/the-price-keeps-falling-for-a-superstar-gilead-drug-in-india